Odesivimab in combination with maftivimab and atoltivimab has been approved as INMAZEB for the treatment of infection caused by Zaire ebolavirus. INMAZEB is a combination of the three recombinant human IgG1kappa monoclonal antibodies that inhibit Zaire ebolavirus, each targeting the Zaire ebolavirus glycoprotein (GP). Maftivimab is a neutralizing antibody that blocks entry of the virus into susceptible cells. Odesivimab is a non-neutralizing antibody that induces antibody-dependent effector function through FcgammaRIIIa signaling when bound to its target. Odesivimab also binds to the soluble form of Zaire ebolavirus glycoprotein (sGP). Atoltivimab combines both neutralization and FcgammaRIIIa signaling activities.